Axonics gets regulatory nod for fourth-generation rechargeable SNM system in Australia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 26 2024
0mins
Source: SeekingAlpha
Regulatory Approval: Axonics has received approval from the Therapeutic Goods Administration in Australia to market its R20 rechargeable sacral neuromodulation system for treating overactive bladder and fecal incontinence in adults.
Product Features: The R20 neurostimulator is designed specifically for these conditions, enhancing treatment options for patients suffering from these issues.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





